A carregar...

Early Biosimilars Face Hurdles to Acceptance: The FDA Has Approved Few, So Lack of Competition Is Keeping Prices High

Biosimilars are a highly anticipated arrival in the pharmacy. However, the undermanned and underfunded FDA struggles to guide, regulate, and approve them.

Na minha lista:
Detalhes bibliográficos
Publicado no:P T
Autor principal: Barlas, Stephen
Formato: Artigo
Idioma:Inglês
Publicado em: MediMedia USA, Inc. 2016
Assuntos:
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4894512/
https://ncbi.nlm.nih.gov/pubmed/27313433
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!